Promotor: H.J.M. de Groot, Co-Promotor: A. Alia

Researchers from Leiden University will develop a new approach to study the biomarkers of Alzeimer’s disease. This approach focusses on the molecular messengers of the cells. The project, led by Thomas Hankemeier and coordinated by Yuliya Shakalisava (Leiden Academic Centre for Drug Research, LACDR),…

In order to better understand the course of Alzheimer’s disease, Frédérique Kok believes that a strategic and structured approach is needed: the Mastermind research approach. With her LUF grant, Kok wants to generate high-quality data to build a mathematical model that can recognize the onset of the…

According to the amyloid cascade hypothesis, accumulation of beta-amyloid (Aβ) peptides initiates the pathological cascade in Alzheimer's disease (AD).

Detection of cerebral beta-amyloid (Abeta) by targeted contrast agents remains of great interest to aid the in vivo diagnosis of Alzheimer's disease (AD). Bis-styrylbenzenes have been previously reported as potential Abeta imaging agents.

Research groups in the Biological & Soft Matter Programme unravel mechanisms in biological processes and develop novel bio-inspired soft materials.

Chemical biologists from Leiden, led by Dr Mario van der Stelt, have discovered substances that can reduce inflammation processes in the brain. This is a first step in the development of potential medicines for the treatment of brain diseases like Alzheimer's and Parkinson's. Published in Proceedings…

Are disturbances to the brain, such as Alzheimer's or autism, linked to specific defects in the underlying communication networks in the brain? If this is the case, subtle changes in the networks can act as a marker for brain disturbances. Neuroscientist Serge Rombouts will be investigating this, together…